{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T04:45:42Z","timestamp":1763959542617},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijcard.2015.08.046","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T02:45:21Z","timestamp":1438742721000},"page":"255-257","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["No evidence for increased prostate cancer risk among calcium channel blockers user"],"prefix":"10.1016","volume":"201","author":[{"given":"Yu","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.08.046_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12954\/PI.12014","article-title":"Epidemiology of prostate cancer in the Asia-Pacific region","volume":"1","author":"Baade","year":"2013","journal-title":"Prostate Int."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10552-009-9477-x","article-title":"Blood pressure and risk of prostate cancer: Cohort Norway (CONOR)","volume":"21","author":"Martin","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0020","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0895-7061(98)00176-9","article-title":"Calcium channel blocker use and the risk of prostate cancer","volume":"11","author":"Vezina","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0030","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","article-title":"The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case\u2013control study","volume":"22","author":"Kemppainen","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","article-title":"Antihypertensive drug use and the risk of prostate cancer (Canada)","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S1047-2797(01)00246-0","article-title":"Hypertension, heart rate, use of antihypertensives, and incident prostate cancer","volume":"11","author":"Fitzpatrick","year":"2001","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","article-title":"Inverse association between prostate cancer and the use of calcium channel blockers","volume":"13","author":"Debes","year":"2004","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10552-008-9280-0","article-title":"Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort","volume":"20","author":"Rodriguez","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0055","author":"Wells"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0065","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pros.22632","article-title":"The association between calcium channel blocker use and prostate cancer outcome","volume":"73","author":"Poch","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.ijcard.2015.08.046_bb0070","first-page":"343","article-title":"Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer","volume":"119","author":"Massaccesi","year":"2014","journal-title":"Radiol. Med."},{"key":"10.1016\/j.ijcard.2015.08.046_bb0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.111.188151","article-title":"Diltiazem enhances the apoptotic effects of proteasome inhibitors to induce prostate cancer cell death","volume":"341","author":"Kaddour-Djebbar","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315302771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315302771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T08:55:17Z","timestamp":1537433717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315302771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":15,"alternative-id":["S0167527315302771"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.046","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No evidence for increased prostate cancer risk among calcium channel blockers user","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}